Strategies For De-Risking Early-Phase Oral Small Molecule Drug Development

Source: Catalent

Many issues related to the performance characteristics of an active pharmaceutical ingredient (API) can be resolved by thoroughly examining various aspects of the molecule before making decisions about solubility enhancement and the delivery method. A team of experts—Lisa Caralli, Science and Technology Director, North America at Catalent Pharma Solutions, Stephen Tindal, Science and Technology Director, Europe at Catalent Pharma Solutions, and Katarina Vulic, Principal Scientist at Novartis Institutes for BioMedical Research—discusses solutions for early-phase drug product development. Topics included risk-reduction strategies, critical formulation considerations, and careful technology selection to stretch the often limited quantities of API available for early studies.

access the Q&A!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Pharmaceutical Online